Paper · 2016 · Open access
Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.
Europe PMC (PubMed Central), 9(4), 188–197 · Published 1 June 2016
In brief
“Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.” is a 2016 paper by Alan L. Shields and 7 co-authors, published in Europe PMC (PubMed Central). OpenAlex counts 14 citations as of 22 November 2026. It is open access: the full text is free to read at Europe PMC (PubMed Central).
- Citations
- 14
- Most cited in
- 2022 (4)
- Field-weighted impact
- 1.70
- References
- 37
- Authors
- 8
Abstract
BACKGROUND: Despite an increased use of patient-reported outcomes (PROs) in oncology clinical trials, integrating the patient perspective into drug approval decisions and documentation has been challenging. OBJECTIVES: To review important regulatory and measurement terminology, and to provide oncology outcomes researchers and those involved with building oncology programs with tools to plan PRO data collection, particularly in relation to drug efficacy claims for drug labeling in the United States. DISCUSSION: When contemplating a PRO measurement strategy for oncology clinical trials, outcomes researchers are challenged in several ways. First, given multiple stakeholders, researchers must communicate with their scientific, commercial, and regulatory colleagues using often misunderstood terms, such as "label," "claim," "end point," "outcome," and "concept." Second, because stakeholders do not always have access to data from early-stage clinical trials and do not contribute to the target drug's profile in early development, researchers are often unable to address the most important question in building a measurement strategy: What do we want to say about our drug? To overcome these challenges, researchers can systematically develop an end point model to facilitate communication among drug development stakeholders using a common language and to link the building blocks of a PRO measurement strategy, including claims, concepts, questionnaires, and end points. We developed a model that characterizes a disease by its proximal signs and/or symptoms and increasingly distal health outcomes to provide researchers potential measurement concepts that can be instrumental in selecting PRO questionnaires for use in studies. CONCLUSION: PRO data collected in clinical trials should be used in drug development to evaluate the drug's efficacy; it is encouraging that US regulators are willing to work with drug sponsors to overcome the challenges associated with the development, implementation, and interpretation of PROs. The tools discussed in this article can facilitate the planning process for oncology researchers, as well as assist in communicating with US regulators.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Shields, A. L., Hao, Y., Krohe, M., Yaworsky, A., Mazar, I., Foley, C., Mehmed, F., & GLOBE, D. R. (2016). Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges. Europe PMC (PubMed Central), 9(4), 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817
MLA 9
Shields, Alan L., et al. “Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.” Europe PMC (PubMed Central), vol. 9, no. 4, 2016, pp. 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817.
Chicago
Shields, Alan L., Yanni Hao, Meaghan Krohe, Andrew Yaworsky, Iyar Mazar, Catherine Foley, Faisal Mehmed, and DENISE R. GLOBE. 2016. “Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.” Europe PMC (PubMed Central) 9 (4): 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817.
Harvard
Shields, A. L. et al. (2016) ‘Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.’, Europe PMC (PubMed Central), 9(4), pp. 188–197. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/5004817.
IEEE
A. L. Shields et al., “Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.,” Europe PMC (PubMed Central), vol. 9, no. 4, pp. 188–197, 2016.
BibTeX
@article{shields2016patient,
title = {{Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.}},
author = {Shields, Alan L. and Hao, Yanni and Krohe, Meaghan and Yaworsky, Andrew and Mazar, Iyar and Foley, Catherine and Mehmed, Faisal and GLOBE, DENISE R.},
journal = {Europe PMC (PubMed Central)},
year = {2016},
volume = {9},
number = {4},
pages = {188--197},
url = {https://www.ncbi.nlm.nih.gov/pmc/articles/5004817}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 1 | |
| 2018 | 1 | |
| 2019 | 2 | |
| 2020 | 1 | |
| 2022 | 4 | |
| 2024 | 1 | |
| 2025 | 1 | |
| 2026 | 3 |
Its field-weighted citation impact is 1.70: it has been cited 1.70 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcomes
- drug approval
- regulatory communication
- measurement concepts
- early-stage clinical trials
- drug development
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Shields, A. L., Hao, Y., Krohe, M., Yaworsky, A., Mazar, I., Foley, C., Mehmed, F., & GLOBE, D. R. (2016). Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges. Europe PMC (PubMed Central), 9(4), 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817
How many times has this paper been cited?
14 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.
Who wrote this paper?
Alan L. Shields, Yanni Hao, Meaghan Krohe, Andrew Yaworsky, Iyar Mazar, Catherine Foley, Faisal Mehmed, DENISE R. GLOBE.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.